Lyell Immunopharma, Inc. (LYEL) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
1.38
+9% vs avg
5yr avg: 1.27
30Y Low0.4·High2.1
ROE
↓
-87.0%
↑-84% vs avg
5yr avg: -47.2%
30Y Low-87%·High-21%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LYEL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lyell Immunopharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $468M | $526M | $167M | $487M | $857M | $1.9B | — | — |
| Enterprise Value | $450M | $508M | $121M | $404M | $802M | $1.7B | — | — |
| P/E Ratio → | -1.25 | — | — | — | — | — | — | — |
| P/S Ratio | 9999.00 | 14614.51 | 2743.40 | 3745.44 | 10.12 | 176.41 | — | — |
| P/B Ratio | 1.38 | 2.12 | 0.44 | 0.74 | 1.03 | 2.02 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LYEL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14107.29 | 1978.99 | 3110.98 | 9.46 | 155.19 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
LYEL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Lyell Immunopharma, Inc. earns an operating margin of -566038.9%. Operating margins have compressed from -190006.2% to -566038.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -87.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -31952.8% | -31952.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -566038.9% | -566038.9% | -588123.0% | -190006.2% | -220.9% | -2016.7% | -2732.6% | -15538.7% |
| Net Profit Margin | -762355.6% | -762355.6% | -562285.2% | -180486.2% | -216.2% | -2349.5% | -2636.3% | -19692.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -87.0% | -87.0% | -66.1% | -31.5% | -20.8% | -30.4% | -36.3% | -31.7% |
| ROA | -66.1% | -66.1% | -55.3% | -27.8% | -17.7% | -24.6% | -27.9% | -23.3% |
| ROIC | -54.0% | -54.0% | -59.2% | -27.4% | -18.9% | -24.1% | -32.7% | — |
| ROCE | -56.0% | -56.0% | -62.3% | -30.6% | -18.9% | -22.1% | -30.4% | -19.1% |
LYEL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $60M exceeds total debt of $42M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.15 | 0.10 | 0.08 | 0.07 | 0.08 | 0.07 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.07 | -0.12 | -0.13 | -0.07 | -0.24 | -0.12 | -0.17 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -2.95 |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($60M) exceeds total debt ($42M)
LYEL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Lyell Immunopharma, Inc.'s current ratio of 5.28x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 16.07x to 5.28x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.28 | 5.28 | 7.06 | 16.07 | 17.59 | 13.40 | 12.53 | 19.97 |
| Quick Ratio | 5.28 | 5.28 | 7.06 | 16.07 | 17.59 | 13.40 | 12.53 | 19.97 |
| Cash Ratio | 5.00 | 5.00 | 6.89 | 15.82 | 17.29 | 13.15 | 12.43 | 19.78 |
| Asset Turnover | — | 0.00 | 0.00 | 0.00 | 0.09 | 0.01 | 0.01 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
LYEL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lyell Immunopharma, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $17M | $13M | $13M | $12M | $12M | $12M | $12M |
Peer Comparison
Compare LYEL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LYELYou | $468M | -1.2 | — | — | -31952.8% | -566038.9% | -87.0% | -54.0% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 ADCT | $478M | -3.4 | — | — | 90.6% | -133.2% | — | — | — |
 CABA | $409M | -2.4 | — | — | — | — | -127.0% | -429.6% | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ALKT | $2B | -37.9 | — | 45.1 | 57.8% | -12.1% | -13.3% | -8.6% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See LYEL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LYEL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LYEL vs FATE
Side-by-side business, growth, and profitability comparison vs Fate Therapeutics, Inc..
Start ComparisonLYEL — Frequently Asked Questions
Quick answers to the most common questions about buying LYEL stock.
What is Lyell Immunopharma, Inc.'s P/E ratio?
Lyell Immunopharma, Inc.'s current P/E ratio is -1.2x. This places it at the 50th percentile of its historical range.
What is Lyell Immunopharma, Inc.'s ROE?
Lyell Immunopharma, Inc.'s return on equity (ROE) is -87.0%. The historical average is -43.4%.
Is LYEL stock overvalued?
Based on historical data, Lyell Immunopharma, Inc. is trading at a P/E of -1.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Lyell Immunopharma, Inc.'s profit margins?
Lyell Immunopharma, Inc. has -31952.8% gross margin and -566038.9% operating margin.